Its valuation is considered fairly valued, Institutional ownership is very high.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Check Cap Ltd's Score
Industry at a Glance
Industry Ranking
298 / 501
Overall Ranking
559 / 4682
Industry
Biotechnology & Medical Research
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
0
analysts
--
Current Rating
--
Target Price
--
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Check Cap Ltd Highlights
StrengthsRisks
Check Cap Ltd is an Israel-based clinical-stage medical diagnostics company. Check Cap Ltd develops C-Scan, patient-friendly preparation-free test designed to detect polyps before they may transform into cancer to enable early intervention and cancer prevention. It's capsule-based screening technology aims to increase screening adherence worldwide. The system utilizes ultra-low-dose X- rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities. C-Scan is non-invasive capsule that is propelled through the gastrointestinal tract by natural motility. C-Scan is comprised of three main components: C-Scan Cap, an ingestible X-ray scanning capsule; C-Scan Track, three miniaturized patches worn on the patient’s back for integrated positioning, control and data recording; and C-Scan View, a proprietary software to process and represent 2D and 3D maps of the inner surface of the colon.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Overvalued
The company’s latest PE is -0.37, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 129.83K shares, decreasing 29.02% quarter-over-quarter.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.12.
Check Cap Ltd is an Israel-based clinical-stage medical diagnostics company. Check Cap Ltd develops C-Scan, patient-friendly preparation-free test designed to detect polyps before they may transform into cancer to enable early intervention and cancer prevention. It's capsule-based screening technology aims to increase screening adherence worldwide. The system utilizes ultra-low-dose X- rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities. C-Scan is non-invasive capsule that is propelled through the gastrointestinal tract by natural motility. C-Scan is comprised of three main components: C-Scan Cap, an ingestible X-ray scanning capsule; C-Scan Track, three miniaturized patches worn on the patient’s back for integrated positioning, control and data recording; and C-Scan View, a proprietary software to process and represent 2D and 3D maps of the inner surface of the colon.
Ticker SymbolCHEK
CompanyCheck Cap Ltd
CEOOvadia (Alex)
Websitehttps://check-cap.com/
FAQs
What is the current price of Check Cap Ltd (CHEK)?
The current price of Check Cap Ltd (CHEK) is 1.610.
What is the symbol of Check Cap Ltd?
The ticker symbol of Check Cap Ltd is CHEK.
What is the 52-week high of Check Cap Ltd?
The 52-week high of Check Cap Ltd is 3.130.
What is the 52-week low of Check Cap Ltd?
The 52-week low of Check Cap Ltd is 0.560.
What is the market capitalization of Check Cap Ltd?
The market capitalization of Check Cap Ltd is 9.42M.
What is the net income of Check Cap Ltd?
The net income of Check Cap Ltd is -25.15M.
Is Check Cap Ltd (CHEK) currently rated as Buy, Hold, or Sell?
According to analysts, Check Cap Ltd (CHEK) has an overall rating of --, with a price target of --.
What is the Earnings Per Share (EPS TTM) of Check Cap Ltd (CHEK)?
The Earnings Per Share (EPS TTM) of Check Cap Ltd (CHEK) is -4.300.